We are focused on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. Biologic drug concentrations vary widely between patients, leading to unnecessary side effects and suboptimal clinical outcomes. By tracking drug levels in individual patients, these high cost treatments can be personalized to improve treatment results and unlock savings for healthcare systems. Aegirbio is setting new standards in this field by pioneering Point of Care and Point of Need tests that can provide results within minutes.
AegirBio is excited to present findings from our recent clinical trial at ACTRIMS Forum! Completed in collaboration with the Rocky Mountain Multiple Sclerosis Research Group, this trial underscores saliva’s potential as a reliable analyte for natalizumab monitoring.
We’re also excited to share a deeper understanding of how patients’ immune systems influence natalizumab metabolism.